Fundraising Fox
/Companies
Sign in

Avirmax

Hayward, US · Founded 2019 · Delaware corporation · 2 known investors

Find your way into Avirmax

Each arrow is one introduction. Sign up to fill in the first one.

83 people can intro you to Haifeng

Ask Glenn Pierce to introduce you to Haifeng Chen

You →Glenn · together at Avigen, Inc. →Haifeng

Sign up to find every way you can get introduced to Avirmax

  • Your email: who you already know at Avirmax, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Avirmax team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases. Through its Avirmax CMC (ACI) division, it also provides bioprocess development and manufacturing services for AAV-based gene therapies to external customers.

BiotechDeep TechMedical Devices

Founders & leadership

HCHaifeng Chen
Haifeng ChenDirector and Treasurer of the IssuerHaifeng Chen is Director and Treasurer of Avirmax with over 10 years of experience in adeno-associated virus vector design, production, and characterization, as well as expertise in gene expression cassette construction and large-scale insect cell culture using Wave bioreactor systems.
SL
Shengjiang LiuNamed on SEC filing

Board

YF
Yu FangDirector of the IssuerGeneral Partner at BioVentures
QK
Qianye Karen LiuDirector of the IssuerGeneral Partner at BioVentures
NC
Nancy ChangDirector of the Issuer

Investors · 2

BioVenturesinferredBelmont

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$3M disclosed across 1 round · 2019

▶$3MraisedNov 2019 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yu FangDirector
  • Qianye Karen LiuDirector
  • Haifeng ChenExecutive Officer, Director
  • Shengjiang LiuExecutive Officer, Director
  • Nancy ChangDirector
Offering amount
$10M
Amount sold
$3M
First sale
Nov 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

1MgThis is a product listing page on an online pharmacy for Tugain Twins 5 Solution, a topical minoxidil-based medicine sold to treat hair loss and promote hair regrowth. The page provides usage instructions, benefits, side effects, and purchase/return details rather than describing a company.
PrescriberPointPrescriberPoint operates an AI-enabled medication access platform that helps clinicians get patients onto prescribed therapies by providing prescribing support, coverage and cost-savings lookups in one place. It serves healthcare providers in the medication access and prescribing space.

Companies working in the same space as Avirmax.

In the news

Avirmax Biopharma Initiates IND-enabling Studies of ABI-201; a Breakthrough Gene Therapy for Dry Age-related Macular Degenerationprnewswire.com · Feb 2025

Frequently asked questions

What does Avirmax do?
Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases. Through its Avirmax CMC (ACI) division, it also provides bioprocess development and manufacturing services for AAV-based gene therapies to external customers.
Who are Avirmax's investors?
Avirmax's investors include 3E Bioventures Capital, BioVentures.
How much funding has Avirmax raised?
Avirmax has disclosed $3M raised across 1 round.
Where is Avirmax headquartered?
Avirmax is headquartered in Hayward, US.